Literature DB >> 20237299

Intradermal administration of ATP does not mitigate tyramine-stimulated vasoconstriction in human skin.

Jonathan E Wingo1, R Matthew Brothers, Juan Del Coso, Craig G Crandall.   

Abstract

Cutaneous vasodilation associated with whole-body heat stress occurs via withdrawal of adrenergic vasoconstriction and engagement of cholinergic "active" vasodilation, the latter of which attenuates cutaneous vasoconstrictor responsiveness. However, the precise neurotransmitter(s) responsible for this sympatholytic-like effect remain unknown. In skeletal muscle, ATP inhibits adrenergically mediated vasoconstriction. ATP also may be responsible for attenuating cutaneous vasoconstriction since it is co-released from cholinergic neurons. The effect of ATP on cutaneous vasoconstrictor responsiveness, however, has not been investigated. Accordingly, this study tested the hypothesis that ATP inhibits adrenergically mediated cutaneous vasoconstriction. To accomplish this objective, four microdialysis probes were inserted in dorsal forearm skin of 11 healthy individuals (mean +/- SD; 35 +/- 11 years). Local temperature at each site was clamped at 34 degrees C throughout the protocol. Skin blood flow was indexed by laser-Doppler flowmetry and was used to calculate cutaneous vascular conductance (CVC; laser-Doppler-derived flux/mean arterial pressure), which was normalized to peak CVC achieved with sodium nitroprusside infusion combined with local skin heating to approximately 42 degrees C. Two membranes were perfused with 30 mM ATP, while the other two membranes were flow matched via administration of 2.8 mM adenosine to serve as control sites. After achieving stable baselines, 1 x 10(-4) M tyramine was administered at all sites, while ATP and adenosine continued to be infused at their respective sites. ATP and adenosine infusion increased CVC from baseline by 35 +/- 26% CVC(peak) units and by 36 +/- 15% CVC(peak) units, respectively (P = 0.75). Tyramine decreased CVC similarly (by about one-third) at all sites (P < 0.001 for main effect and P = 0.32 for interaction). These findings indicate that unlike in skeletal muscle, ATP does not attenuate tyramine-stimulated vasoconstriction in human skin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237299      PMCID: PMC2867519          DOI: 10.1152/ajpregu.00846.2009

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  35 in total

1.  Neurally mediated vasoconstriction is capable of decreasing skin blood flow during orthostasis in the heat-stressed human.

Authors:  Manabu Shibasaki; Scott L Davis; Jian Cui; David A Low; David M Keller; Sylvain Durand; Craig G Crandall
Journal:  J Physiol       Date:  2006-06-22       Impact factor: 5.182

2.  Does local heating-induced nitric oxide production attenuate vasoconstrictor responsiveness to lower body negative pressure in human skin?

Authors:  David A Low; Manabu Shibasaki; Scott L Davis; David M Keller; Craig G Crandall
Journal:  J Appl Physiol (1985)       Date:  2007-02-01

3.  Baroreflex control of the cutaneous active vasodilator system in humans.

Authors:  D L Kellogg; J M Johnson; W A Kosiba
Journal:  Circ Res       Date:  1990-05       Impact factor: 17.367

4.  Modification of the cutaneous vascular response to exercise by local skin temperature.

Authors:  W F Taylor; J M Johnson; D S O'Leary; M K Park
Journal:  J Appl Physiol Respir Environ Exerc Physiol       Date:  1984-12

5.  Effect of elevated local temperature on cutaneous vasoconstrictor responsiveness in humans.

Authors:  Jonathan E Wingo; David A Low; David M Keller; R Matthew Brothers; Manabu Shibasaki; Craig G Crandall
Journal:  J Appl Physiol (1985)       Date:  2008-12-04

6.  Prostanoids contribute to cutaneous active vasodilation in humans.

Authors:  Gregg R McCord; Jean-Luc Cracowski; Christopher T Minson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-09       Impact factor: 3.619

7.  Inhibition of KATP channel activity augments baroreflex-mediated vasoconstriction in exercising human skeletal muscle.

Authors:  David Melvin Keller; Shigehiko Ogoh; Shane Greene; A Olivencia-Yurvati; Peter B Raven
Journal:  J Physiol       Date:  2004-09-02       Impact factor: 5.182

8.  Muscle interstitial ATP and norepinephrine concentrations in the human leg during exercise and ATP infusion.

Authors:  Stefan P Mortensen; José González-Alonso; Jens-Jung Nielsen; Bengt Saltin; Ylva Hellsten
Journal:  J Appl Physiol (1985)       Date:  2009-10-01

9.  Purinergic cotransmission.

Authors:  Geoffrey Burnstock
Journal:  Exp Physiol       Date:  2008-08-22       Impact factor: 2.969

10.  Nitric oxide is not permissive for cutaneous active vasodilatation in humans.

Authors:  Brad W Wilkins; Lacy A Holowatz; Brett J Wong; Christopher T Minson
Journal:  J Physiol       Date:  2003-03-21       Impact factor: 5.182

View more
  4 in total

1.  Intradermal administration of ATP augments methacholine-induced cutaneous vasodilation but not sweating in young males and females.

Authors:  Naoto Fujii; Lyra Halili; Maya Sarah Singh; Robert D Meade; Glen P Kenny
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-19       Impact factor: 3.619

2.  The ubiquitous ATP molecule: could it be the elusive thermal mediator igniting skin perfusion and sweating in the heat-stressed human?

Authors:  José González-Alonso; Kameljit K Kalsi
Journal:  J Physiol       Date:  2015-06-01       Impact factor: 5.182

3.  Changes in dermal interstitial ATP levels during local heating of human skin.

Authors:  Jayson R Gifford; Cory Heal; Jarom Bridges; Scott Goldthorpe; Gary W Mack
Journal:  J Physiol       Date:  2012-10-08       Impact factor: 5.182

4.  Cutaneous vascular and sweating responses to intradermal administration of ATP: a role for nitric oxide synthase and cyclooxygenase?

Authors:  Naoto Fujii; Ryan McGinn; Lyra Halili; Maya Sarah Singh; Narihiko Kondo; Glen P Kenny
Journal:  J Physiol       Date:  2015-04-17       Impact factor: 5.182

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.